Angelman Syndrome clinical trials at UCSF

1 research study open to eligible people

Showing trials for

  • GTX-102 in Pediatric Subjects With AS

    open to eligible people ages 4-17

    The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with deletion-type Angelman Syndrome (AS).

    San Francisco, California and other locations

Our lead scientists for Angelman Syndrome research studies include .

Last updated: